Innovative research demonstrates enhanced cancer treatment using lipid nanoparticles targeting perivascular macrophages.

August 12, 2024 – Baltimore, MD

LipExoGen, a leader in advanced drug delivery technologies, in collaboration with the University of Sheffield, is pleased to announce the
publication of their pioneering study in the Journal for Immunotherapy of Cancer. The study presents a novel approach to immunotherapy for prostate cancer, utilizing lipid nanoparticles (LNPs) to deliver a potent STING agonist directly to perivascular macrophages in tumors.

“This is a significant breakthrough in cancer treatment,” said Christopher Bailey, Director of the Formulations Division at LipExoGen. “Our lipid nanoparticles offer a completely new form of immunotherapy by precisely targeting immune cells within the tumor microenvironment, thereby boosting the body’s natural anti-tumor response.”

Key Findings:

• Targeted Delivery: The study demonstrates that LNPs coated with an antibody to folate receptor beta (FRβ) successfully deliver the
  STING agonist, 2′3′-cGAMP, to perivascular tumor-associated macrophages (TAMs) in prostate tumors.
• Enhanced Immune Response: The targeted delivery of 2′3′-cGAMP stimulates the STING pathway in TAMs, leading to the production of interferon beta (IFNβ), which activates surrounding immune cells, including CD4+ and CD8+ T cells, and NK cells.
• Delayed CRPC: This approach significantly delays the onset of CRPC in preclinical models, potentially extending the therapeutic window for ADT.

“By targeting the immune cells within the tumor microenvironment, we are opening new avenues for cancer immunotherapy,”
said Professor Claire E. Lewis of the University of Sheffield, corresponding author of the study. “This study could lead to more effective treatments for patients and improve outcomes in prostate cancer.”

About LipExoGen

LipExoGen specializes in cutting-edge drug delivery systems, focusing on enhancing therapeutic outcomes through precision medicine. Their
innovative approaches aim to transform the treatment landscape for various diseases.

About the University of Sheffield

A leading research institution, the University of Sheffield is committed to pioneering research and innovation across a wide range of disciplines. Their work in cancer research is recognized globally for its impact and contribution to advancing medical science.

Contact Information:

Email: info@lipexogen.com
Phone: 410-231-3496

For more details on the study, please visit the Journal for Immunotherapy of Cancer